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Abstract: Objective: To analyze the increasing trend of intravitreal triamcinolone (IVTA) use in the treatment of retinal 
vein occlusion-related macular edema. Methods: We performed MEDLINE/PUBMED searches (September 1984 - De-
cember 2007) to identify articles containing the keywords macular edema and triamcinolone. Case reports, reviews and 
abstracts were identified from references in the reviewed literature. This review focuses on literature published during the 
past 7 years with more than two-thirds of the articles that we reviewed being printed during the past 5 years. These reports 
analyzed the success of IVTA in the treatment of macular edema over a 12 month course of time. Results: The majority of 
studies suggested promising results for short time periods (4-6 months) after IVTA treatments. However, long term results 
were not encouraging. Conclusions: The success of IVTA therapy for short durations has been the impetus for develop-
ment of sustained release devices to be used in the treatment of macular edema associated with various retinal diseases in-
cluding edema related to retinal vein occlusion. 
Keywords: Intravitreal triamcinolone, macular edema, retinal vein occlusion. 
INTRODUCTION 
  Retinal vein occlusion (RVO) is second only to diabetic 
retinopathy as the most common form of retinal vascular 
disease in the United States [1]. The cumulative 10-year in-
cidence of retinal vein occlusion was estimated to be 1.6% in 
the Blue Mountains population study of individuals aged 49 
years and older [2]. 
  Although the pathophysiology of RVO is poorly under-
stood, an important final common pathway is retinal ische-
mia. Some of the major pathological effects of ischemia on 
tissue includes breakdown of inner blood–retinal barrier [3], 
increased VEGF production [4] and generalized inflamma-
tion of retinal tissue by release of prostaglandin and interleu-
kins [5]. 
  The clinical course of central retinal vein occlusion 
(CRVO) and branch retinal vein occlusion (BRVO) may 
differ but a major cause of visual loss is macular edema in 
both the diseases [6]. Other causes of visual loss are ische-
mia and the presence of central hemorrhage. 
  Therapies in RVO have two aims. One is to reduce macu-
lar edema and the other is to prevent neovascularization 
caused by retinal ischemia. Many therapies such as laser 
photocoagulation, anticoagulation, hemodilution, laser-
induced chorioretinal anastomosis, anti-VEGF treatment, 
vitrectomy, sheathotomy, and intravitreal steroids have been 
used to treat these complications [6]. 
  Among these treatments, only anti-VEGF medications, 
laser photocoagulation, and intravitreal steroids address the 
pathophysiological mechanisms responsible for vein occlu-
sion. Anti-VEGF medications (Ranibizumab and Bevacizu-
mab) have excellent effects except in cases of severely 
ischemic retina. Laser photocoagulation improves visual   
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acuity (VA) in patients with BRVO associated macular 
edema but is ineffective in improving VA in patients with 
macular edema associated with CRVO [7]. Overall, laser 
treatment of perfused macular edema only minimally im-
proves vision and offers little hope for patients with poor 
pretreatment visual acuity. The benefits for ischemic macular 
edemas are still not known. 
  Reports have suggested a role for surgical interventions 
in the treatment of retinal vein occlusion but results of ran-
domized clinical trials are not favorable [8-10]. 
  Being a less traumatic option of treatment, intravitreal 
steroids are gaining popularity. At this time intravitreal 
triamcinolone (IVTA) is the most frequently used steroid. 
Small case series confirmed the visual benefit of IVTA in 
both perfused and ischemic macular edema. Studies have 
revealed that it reduces macular edema in both CRVO and 
BRVO [10, 11]. Greater effects were observed on 
nonischemic CRVO than ischemic CRVO [12]. 
  There are some complications of IVTA such as increased 
intraocular pressure (IOP), cataract formation [13], and ster-
ile endophthalmitis [14]. A major limiting factor of in-
travitreal steroids is their short duration of action. Many 
studies revealed that effects of IVTA treatment persist for 
only 4-6 months [15]. 
RESULTS 
Best Corrected Visual Acuity 
  Three of four studies showed improved best corrected 
visual acuity (BCVA) for approximately 3 months after 
IVTA injection but there was a subsequent decline in the 
vision at 1 year. Table 1 shows the BCVA at follow up visits 
of 1, 3 and 12 months. 
Central Foveal Thickness 
  Significant improvement in the central foveal thickness 
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CRVO after IVTA injections [16-18, 20-24]. Table 2 shows 
that the central foveal thickness as measured by optical co-
herence tomography (OCT) dramatically decreases through 
the 3
rd month post treatment. However at the 6 month visit 
there is no significant difference from the baseline thickness 
and in most of the studies the macular edema had returned. 
Need to Repeat Injection 
  Most of the studies showed that IVTA injections needed 
to be repeated between the 4
th and 12
th months during the 
follow up period [16-18]. 
Complications 
  In the published literature, the most common complica-
tion of IVTA treatment was a transient rise in IOP, and was 
controlled with topical medication [26-31]. Wingate and 
coworkers reported that approximately 30% of the study 
group develop a significant rise (5 mm Hg) in IOP above 
baseline during the first 3 months [30]. Other reported com-
plications were cataract progression  and pseudohypopyon 
[27, 31, 32]. Progression of nuclear sclerotic cataract was 
reported in 22% of an older group following a single injection 
[27]. In the nine published reports of IVTA, a total of 224 
eyes in 224 patients have been treated without any reported 
complication of endophthalmitis [26-31, 33, 34]. 
DISCUSSION 
  The natural history outcome of RVO is very poor [35, 
36]. Macular edema associated RVO has always been a dif-
ficult condition to treat. Until recently there has been no 
proven treatment of this pathology. The Central Vein Occlu-
sion Study Group showed that there was no significant dif-
ference found in VA between laser-treated and untreated 
eyes at any follow up time points [35]. 
  There are several case reports showing short-term reduc-
tion in macular edema due to CRVO and BRVO as measured 
by OCT following IVTA [11, 23, 37, 38]. Jonas et al. re-
ported significant improvement in VA in both eyes after in-
jection with 25 mg of IVTA in a patient with macular edema 
due to CRVO [39]. They found decreased fluorescein leak-
age and did not find any significant complications except 
mild cataract progression and transient increase in IOP. Park 
et al. reported significant anatomical and functional im-
provement in 10 eyes with macular edema due to 
nonischemic CRVO. In their study of 4mg IVTA injections 
and an average follow up of 4.8 months, they found that 60% 
of the eyes gained 2 lines of VA [23]. 
 Greenberg  et al. [34] studied a patient with bilateral 
macular edema associated with CRVO. After an intravitreal 
injection of 4 mg TA, there was significant improvement in 
the acute CRVO eye but no improvement in VA in the eye 
with chronic CRVO. A second injection was performed due 
to decline in the VA after 6 months. OCT showed a decrease 
of macular edema with restoration of normal macular anat-
omy in both eyes. Fortunately, there was no elevation of IOP 
in this patient. 
  Bashshur [40] studied VA changes in 40 eyes with macu-
lar edema due to nonischemic CRVO. Twenty eyes were 
treated by a single intravitreal injection of 4 mg of TA, and 
the rest were only observed for the natural course of the dis-
ease. Baseline BCVA was from 20/50 to 20/200. Over 10 
months, 12 (60%) of the 20 treated eyes had a final visual 
acuity of 20/40 or better, while only 4 (20%) of the 20 eyes 
in the observation group had a final visual acuity of 20/40 or 
better. 
  Ip & Kumar [37] injected 4 mg IVTA in two patients 
with macular edema from CRVO and observed an improve-
ment in BCVA in both cases. In one case, concerning a pa-
tient with nonischemic CRVO, the improvement lasted until 
the 6 month follow up visit. In the other case, involving 
ischemic CRVO, the effect did not last and BCVA after 3 
months was worse than before the injection. 
  Chen and associates [25, 41] reported a favorable re-
sponse to IVTA in a patient with ischemic macular edema 
associated with BRVO while the study by Jonas and co-
workers revealed no improvement in ischemic macular 
edema in their 2 patients. In their prospective comparative 
nonrandomized study [42], Jonas treated 10 eyes with 20 mg 
Table 1.  Summary of Improvement of Best Corrected Visual Acuity After IVTA Injections 
 
Baseline BCVA  1 Month After IVTA  3 Months After IVTA  12 Months After IVTA  Ref. 
20/400 20/300  20/300  8/200  [16] 
20/100 20/50  20/50  20/70  [17] 
20/300 20/166  20/130  20/270  [18] 
worse than 20/50  better than 20/50  better than 20/50  better than 20/40  [19] 
Table 2.  Summary of Central Foveal Thickness After IVTA Injections 
 
Baseline Central Foveal Thickness  1 Month After IVTA  3 Months After IVTA  6 Months After IVTA  Ref. 
590 m 212  m 193  m 281  m [12] 
400 m 228  m 256  m 352  m [25] 
468 m 310  m 311  m 365  m  [20] 
476 m 329  m 389  m 498  m [21] 
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to 25 mg IVTA for macular edema associated with BRVO. 
Their study revealed significant improvement in VA at one 
month post injection but the long term effect was not re-
ported. Other studies revealed a decline in the BCVA after 
initial improvement [23, 34, 43, 44]. 
  The most likely cause of the short duration of action of 
IVTA is elimination of the drug by diffusion. Following in-
travitreal injection of 4 mg, measurable levels of TA have 
been detected in aqueous humor up to 3 months [15]. In ad-
dition, triamcinolone has been found in aqueous up to 1.5 
years following single injections of 20 to 25 mg [45]. 
SUMMARY AND FUTURE 
  IVTA is frequently used for the treatment of various in-
traocular neovascular and edematous conditions such as 
RVO and diabetic retinopathy. Typically, steroids are admin-
istered intravitreally because steroids given as drops, sys-
temically, or injected into the subconjunctival and sub-
Tenon’s space do not reach high enough concentrations to be 
effective. Additionally, corticosteroids used systemically for 
prolonged periods of time increased the risk for systemic 
side effects. 
  Studies demonstrated the efficacy of IVTA in reducing 
macular edema in both CRVO [23, 34] and BRVO [11, 38, 
41]. In a majority of these reports, there is a short-term effect 
of improved retinal thickness, decreased exudation and im-
proved visual acuity, but long-term results were not favor-
able. It is probable that patients with an initial improvement 
but subsequent decline in BCVA after IVTA may benefit 
from repeated treatments but re-injections always involve 
increased risks and frequent follow up. Steroid implants 
would perhaps obviate this by providing the edematous mac-
ula a lower but steady dose of steroid. At the present time 
there are ongoing clinical trials to assess the efficacy of in-
travitreal steroid implants. 
  The only FDA approved steroid implant Retisert (Bausch 
& Lomb, Rochester, NY) contains fluocinolone acetonide 
within a tiny drug reservoir (0.59 mg) which delivers sus-
tained levels into the vitreous cavity and is sutured to the 
sclera through a trans-pars plana incision. In 2005, the FDA 
approved the Retisert implant for the treatment of chronic 
noninfectious uveitis affecting the posterior segment of the 
eye [46]. This implant releases drug at an initial rate of 0.6 
μg per day, with dosage decreasing after the first month to a 
steady rate of 0.3 μg to 0.4 μg per day for approximately 30 
months. The most common serious adverse events in the 
implanted eyes were cataract development requiring extrac-
tion and IOP increase. Ninety-five percent of phakic im-
planted eyes needed cataract surgery, and 35% of implanted 
eyes experienced increased IOP. A filtering procedure was 
needed in 28% of implanted eyes, and explantation of the 
insert was done in 5% of eyes to manage IOP. This fluoci-
nolone acetonide implant also has been studied in a multi-
center, randomized, controlled clinical trial for the treatment 
of diabetic macular edema (DME). Patients were randomized 
2:1 to receive either a 0.59 mg fluocinolone acetonide im-
plant or standard of care, which were either repeat laser 
treatments or observation. 
  The Medidur implant (Alimera Sciences, Alpharetta GA) 
also contains fluocinolone acetonide but is much smaller 
than the Retisert implant. Although the Medidur is a reser-
voir implant, it is injected into the vitreous cavity with a 25 
gauge syringe and is not sutured to the eye wall, therefore, it 
is allowed to float freely in the vitreous space. Medidur has 
two models; one is designed to last approximately 3 years 
and other lasts approximately 18 months. Enrollment in the 
phase 3 FAME (Fluocinolone Acetonide in Diabetic Macular 
Edema) trial, which is evaluating a daily dose of 0.2 μg and 
0.5 μg of fluocinolone acetonide to the retina, has been com-
pleted. FAME is a double-masked, randomized, multicenter 
study involving more than 900 patients in the United States, 
Canada, Europe and India. Safety and efficacy will be as-
sessed at 2 years, and patients will be followed for 3 years. 
Results from this trial will help to determine if Medidur FA 
is effective and capable of reducing the steroid induced side 
effects seen in the Retisert trial. 
  There is also recent interest in the Posurdex drug delivery 
system (Allergan, Inc., Irvine, CA) which is a sustained de-
livery formulation of dexamethasone. The Posurdex implant 
is biodegradable, unlike the Retisert and Medidur implants, 
and undergoes hydrolysis with degradation to lactic acid and 
glycolic acid, two naturally occurring metabolic by-products 
that are then further broken down to water and carbon diox-
ide. The implant is inserted into the vitreous cavity and floats 
freely in the vitreous base. Two different dexamethasone 
dose implants were evaluated in a 6 month, Phase 2, multi-
center, randomized clinical trial [47]. 
  The 315 patients in the Posurdex trial had persistent 
macular edema due to either diabetic retinopathy (n=172), 
RVO (n=102), Irvine-Gass syndrome (n=27) or uveitis 
(n=14). In each patient, 1 eye was randomized to treatment 
with either a 350 μg dose of Posurdex, or a 700 μg dose of 
Posurdex. At the primary endpoint (day 90 of the study), 2% 
of the patients who were implanted with the 350 μg dose of 
Posurdex had an increase in IOP of 10 mm Hg or more from 
baseline, compared with 2% of patients in the 700 μg group 
and 1% of patients in the observation arm. All were managed 
with either observation or topical IOP-lowering medication. 
No patient required any surgical intervention to control IOP. 
Cataracts were present in 15% of the 350-μg group, 17.8% 
of the 700 μg group and 12.4% of the observation group 
(P<0.001 vs observation). The efficacy results showed a dose 
response curve that was observed for all subsets of patients 
based on the underlying cause of macular edema. Overall, 
18.1% of eyes in the 700 μg group showed a three line im-
provement in BCVA at 180 days compared to 7.6% in the 
observation group and 14.6% in the 350 μg group. Clinically 
and statistically significant reductions in macular thickness 
by OCT and leakage by fluorescein angiogram were also 
observed in a dose response fashion. Phase 3 trials are un-
derway evaluating the Posurdex implant for patients with 
either DME or macular edema caused by RVO. 
  The prospective, randomized, double-masked STRIDE 
(Sustained Triamcinolone Release for Inhibition of Diabetic 
Macular Edema) trial assesses the safety and tolerability of 
the I-vation TA (SurModics, Eden Prairie, MN) in 30 pa-
tients. Dugel and colleagues reported results of a 6 month 
interim analysis. In the study, patients were randomized to 
either a slow-release or fast-release implant containing 925 
μg of TA. At 6 months, the proportion of patients with 
BCVA of at least 70 ETDRS letters increased from 14% to 
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fast-release group. 8% of patients in the slow-release group 
and 18% in the fast-release group gained more than 15 let-
ters. Macular thickness improvement was reported with the 
use of both implants. Mean IOP increased from 13.9 mm Hg 
to 16.1 mm Hg in the slow group and from 14.3 mm Hg 
to16.4 mm Hg in the fast group at 6 months. The patients in 
the STRIDE study will be followed for 3 years. 
  The National Eye Institute sponsored study called the 
Standard Care vs COrticosteroid for REtinal Vein Occlusion 
(SCORE) trial is a multicenter, randomized, Phase III trial to 
compare the effectiveness and safety of standard care versus 
IVTA injection(s) for the treatment of macular edema asso-
ciated with CRVO and BRVO. As of February 29, 2008 
when enrollment was concluded, a total 682 subjects with 
CRVO (271) or BRVO (411) had been randomized in a 1:1:1 
ratio to one of three groups: standard care, IVTA 4 mg, or 
IVTA 1 mg. Follow up examinations are every 4 months for 
3 years and will collect ophthalmic data, including VA, IOP, 
OCT and fundus photography. Fluorescein angiography will 
be performed at 4, 12 and 24 months. Based on protocol-
specific guidelines, repeat intravitreal injections of TA and 
repeat laser treatment will be provided as clinically indi-
cated. The primary outcome is improvement by 15 or more 
letters from baseline in best-corrected ETDRS visual acuity 
score at the 12 month visit. Secondary outcomes include 
changes from baseline in best-corrected ETDRS visual acu-
ity score, changes in retinal thickness as assessed by stereo-
scopic color fundus photography and OCT and adverse ocu-
lar outcomes. 
  Results of the SCORE trial will provide answers regard-
ing the use of IVTA in both CRVO and BRVO. 
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